Biotech Values

[genisi]

Roche is certainly pursuing this strategy see this phase III trial of Tarceva vs.chemo, in 1st line NSCLC patients with EGFR mutation positive (completion expected end of 2010).

http://clinicaltrials.gov/ct2/show/NCT00446225